We are delighted to share the news that Rubén Prieto-Díaz has successfully defended his doctoral thesis, earning the highest accolades.
In the course of his research, Ruben validated the A2B receptors in the realm of Cancer immunotherapy. He also synthesized an extensive array of A2B antagonists, pinpointing several promising candidates with excellent A2B affinity and selectivity. Furthermore, he undertook the development and optimization of new candidates, unraveling their effectivity for the treatment of glioblastome and colon cancer.
Congratulations, Rubén! May your future endeavors be filled with success and fulfillment!
